Andrew Huberman, PhD (@hubermanlab), is a neuroscientist and tenured professor in the Department of Neurobiology at Stanford University’s School of Medicine. He has made numerous important contributions …
In this conversation, Rick and Isra cover much ground on psychedelics, from set & setting and preparation and integration to Rick’s best practices, personal LSD, MDMA and psilocybin journeys …
You’re having a VR program that’s supposed to somehow remind you of your own inner imagery, so it will be not as precise as your own imagination. -Rick Doblin Originally appearing here (Archived)
In its capacityas afinancial news and media outlet,Benzinga has added six new members to its Psychedelics Advisory Council. The new members includerenowned authorAmanda Siebert; Revitalist Lifestyle & …
Green Bay Packers quarterback Aaron Rodgers and prominent podcaster Tim Ferriss are among thedozens of speakersmaking a trip to Denver this summer for a conference dedicated to all things psychedelics. …
“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” Rick Doblin, executive director …
“Australia’s policy change is one that every country should consider: suffering people, regardless of nationality, need more opportunities to access novel treatments,” MAPS founder and director Dr. …
After decades of criminalization, Australia’s government said Friday that it will legalize the prescription of MDMA and psilocybin for the treatment of two medical conditions, a historic move hailed …
Summary: “At this moment, when two successful Phase 3 studies of MDMA-assisted therapy for PTSD have brought us closer to potential FDA approval than ever before, MAPS and MAPS PBC must faithfully …
Summary: Technology Networks explores the rapid evolution seen in the world of science today, highlighting the potential benefits of psychedelic-assisted therapy. “The use of marijuana for medical …
In early January, MAPS announced that MAPP2 met pre-specified primary and key secondary endpoints and that it planned to file a new drug application submission in the third quarter of 2023. At the end …
Originally appearing here (Archived)